RhoVac’s reports positive results from the 12 months follow-up of the company’s phase I/II clinical study
RhoVac AB (“RhoVac”) reported today, 4th July, 2019, positive top-line results on safety and immune response in the long-term follow-up of the Company’s phase I/II clinical trial RhoVac-001.In total 22 prostatectomised cancer patients received RV001 treatment over a period of approximately 30 weeks. Following completion of treatment, all patients were monitored over a 12 months follow-up period. At 3, 6, 9 and 12 months after completion of treatment with RV001, the patients were evaluated for treatment related reactions and for immunological response. In summary, the results from the long-